Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) to collaborate on the discovery of new candidate compounds for targeted protein degraders (TPD).
Axcelead DDP’s DegLead Platform to Support Astellas’ TPD Discovery
Axcelead DDP, a company focused on targeted protein degradation, boasts the DegLead Platform, an integrated service solution that will be utilized to support Astellas’ TPD discovery efforts and the research and development of breakthrough new drug candidate compounds. This collaboration aims to leverage Axcelead DDP’s expertise in TPD to enhance Astellas’ drug discovery capabilities.
No Financial Details Disclosed for the Partnership
The financial details of the partnership between Astellas Pharma and Axcelead DDP have not been disclosed, indicating a focus on the strategic value of the collaboration rather than its monetary aspects. This partnership highlights the growing interest in targeted protein degraders as a promising approach in drug discovery and development.-Fineline Info & Tech
